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As more options become available to treat moderate to severe
psoriasis, more questions arise regarding the long-term e¡ect
and risk associated with treatment. The choice of systemic thera-
pies consists either of therapeutic modalities having a true carci-
nogenic e¡ect such as psoralens combined with ultraviolet-A
radiation (PUVA) and UVB or systemic immunosuppressants
such as methotrexate, cyclosporine which may potentiate the car-
cinogenic e¡ect of PUVA (Stern et al, 1979; Lindel˛f et al, 1999;
Paul et al, 2003). There is evidence that PUVA has the highest
risk for inducing non-melanoma skin cancer (NMSC) and
the risk may be signi¢cantly lower for UVB therapy (Stern and
Lunder, 1998; Paul et al, 2003). As demonstrated in animals and in
humans, systemic immunosuppression can potentiate the carcino-
genic e¡ect of UV light (Daynes et al, 1979). In transplant patients
who are subjected to long-term continuous systemic immuno-
suppression, the risk of skin cancer is closely related with the de-
gree of immunosuppression, whichever therapeutic regimen is
used (Dantal et al, 1998; Sheil, 2001). In psoriasis patients, the risk
of skin cancer in patients receiving systemic immunosuppressants
is heavily dependent upon their previous use of PUVA (Marcil
and Stern, 2001; Paul et al, 2003). In order to guide clinical deci-
sions, physicians and patients need to have the best knowledge
about the magnitude of the risk and its relevance to the indivi-
dual patient.
In the present paper Nijsten and Stern (2003) report on the risk
of non-melanoma skin cancer (NMSC) in the PUVA cohort
study after 25 years of follow-up. They con¢rm previous reports
that exposure to PUVA is the most important risk factor for
NMSC and that there is a strong and linear relationship between
the risk magnitude and the level of exposure to PUVA as ex-
pressed by number of PUVA sessions. Based on a within-cohort
comparison, they suggest that discontinuation of PUVA for 15
years is not associated with a reduction in the risk of NMSC.
This conclusion is intriguing and raises a few questions.
The induction of skin cancer after PUVA is a relatively
rapid phenomenon. An increase in the incidence of NMSC in
the PUVA cohort study was already observed after less than
3 years of follow-up (Stern et al, 1979). Although the hazard
function of NMSC induction after PUVA is not completely
understood, one would expect some reduction of the risk 10^15
years after discontinuing PUVA. Therefore it seems important to
examine the validity of the conclusion of the analysis by Nijsten
and Stern.
The ¢rst question regards the internal validity: how strongly
does the data support the conclusion that the risk of skin cancer
in patients is not reduced after discontinuation of PUVA? A for-
mal demonstration that PUVA cessation is associated with a re-
duction in the risk of skin cancer would require randomization
and prospectively following two groups of patients who either
continue PUVA or stop treatment. Caution about inference
should be exercised when the conclusion is supported by a retro-
spective within-cohort comparison. At the time of the present
analysis of the PUVA cohort study, the attrition rate due to death
or loss of follow-up exceeds 50%. Selection bias is a common
problem of most cohort studies and is likely to occur during
long-term follow-up. One type of selection bias that needs to be
considered carefully is the ‘‘healthy user’’ e¡ect, whereby patients
who are most susceptible to skin cancer have left the cohort of
PUVA users as a result of a skin cancer or other related side-ef-
fects. Consequently patients who continue PUVA are considered
‘‘healthy users’’and may be less susceptible to skin cancer than are
those who have stopped PUVA. Evidence of such a bias was
documented in a previously published analysis of the same cohort
(Katz et al, 2002). The authors showed that counter-intuitively for
both squamous-cell and basal-cell carcinoma, patients receiving
no post-¢rst tumor PUVA treatment at all had a higher risk of
second tumors than those who received a low rate of post-tumor
PUVA treatment. Consequently, the ‘‘healthy user’’e¡ect bias may
have confounded the evaluation of the risk of skin cancer after
discontinuation of PUVA in the analysis by Nijsten and Stern.
The results are probably valid for a subpopulation of patients
with a higher susceptibility to the carcinogenic e¡ect of PUVA
(e.g., PUVA-treated patients who have developed a ¢rst NMSC).
More research is needed to assess how the risk of skin cancer var-
ies upon discontinuation of PUVA.
The second question regards external validity: how relevant
are the ¢ndings reported to the population of patients we are
treating today? Clearly patients from the PUVA cohort study
represent a highly selected sample of su¡erers with severe
psoriasis from tertiary care centers in the United States who
were heavily exposed to PUVA starting in 1975^76. Studies
have shown that the risk of NMSC with PUVA is much less
in European patients, likely due to lower background rate of
NMSC in Europe and lower degree of exposure to PUVA.
Additionally, since the ¢rst publication of an increased incidence
of NMSC in patients treated with PUVA, a number of measures
have been taken by physicians to reduce the risk such as limita-
tion in the cumulative number of PUVA sessions, dose reduc-
tions of patients with skin type I and II, and discontinuation of
PUVA in patients with actinic keratosis or skin cancer (Schmutz
et al, 2000). As a result of these measures, it is likely that the risk
of NMSC in patients treated with PUVA today is much lower as
compared to 25 years ago. Unfortunately no data from a prospec-
tive cohort study enrolling patients in 1990^2000 are available to
con¢rm this.
Cohort studies constitute the central vehicle of understanding
the natural course of a disease and the potential of long-term
treatment e¡ects. Cohort studies complement randomized con-
trolled trials in assessing the long-term bene¢ts and risks of ther-
apeutic interventions. It is striking that more than 50 years after
the introduction of methotrexate, the ¢rst systemic agent to treat
severe psoriasis, so few prospective long-term cohort studies have
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investigated the natural course of psoriasis and the e¡ects and risk
associated with treatments. Fortunately, as a consequence of new
direction given by regulatory agencies, post marketing long-term
safety studies are likely to be more frequent in the future to fully
evaluate the long-term safety of systemic agents approved for the
treatment of psoriasis (Alefacept. Product Approval Letter 2003).
The opinion was expressed recently that the best way to conduct
postmarketing safety studies would be to contract them exclu-
sively to academic investigators based on the fact that researchers in
the pharmaceutical industry may be biased by con£ict of interest
(Stern, 2003). Such a view may have been popular some 30 years
ago. However, academic investigators are not exempt from
con£ict of interest or scienti¢cally questionable practices such as
data dredging, posthoc analysis or selective reporting of the most
‘‘interesting’’ results (Buyse et al, 1999). Moreover, the world of
drug development and pharmaco-epidemiology has changed dra-
matically since the initiation of the PUVA cohort. Major recent
therapeutic advances in medical science, including dermatology,
are the result of collaborative e¡orts of academic and non-aca-
demic investigators, researchers from the pharmaceutical industry,
regulatory authorities and patients who enrolled in clinical stu-
dies. In order not to repeat the de¢ciencies from the past in terms
of evaluating and understanding psoriasis treatments, a true colla-
boration among all parties based on mutual respect and continu-
ous dialog is necessary. All available expertise should be invested
to appropriately design and build the ‘‘evidence map’’ that will al-
low physicians and psoriasis patients to navigate safely between
Scylla and Charybdis. The task in front of us is formidable but
Ithaca is certainly on the horizon.
I am grateful to Professor Louis Dubertret for his review of the manuscript.
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